🚀 VC round data is live in beta, check it out!
Lantern Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lantern Pharma and similar public comparables like Jasper Therapeutics, Elicera Therapeutics, Tempest Therapeutics, Marker Therapeutics and more.
Lantern Pharma Overview
About Lantern Pharma
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group’s growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Founded
2013
HQ
Employees
24
Website
Financials (LTM)
EV
$18M
Lantern Pharma Financials
Lantern Pharma reported last 12-month revenue of —.
In the same LTM period, Lantern Pharma generated had net loss of ($18M).
Revenue (LTM)
Lantern Pharma P&L
In the most recent fiscal year, Lantern Pharma reported revenue of — and EBITDA of ($18M).
Lantern Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($18M) | XXX | XXX | XXX |
| Net Profit | ($18M) | XXX | ($17M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lantern Pharma Stock Performance
Lantern Pharma has current market cap of $28M, and enterprise value of $18M.
Market Cap Evolution
Lantern Pharma's stock price is $2.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $28M | 0.0% | XXX | XXX | XXX | $-1.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLantern Pharma Valuation Multiples
Lantern Pharma trades at (1.0x) EV/EBITDA.
Lantern Pharma Financial Valuation Multiples
As of April 20, 2026, Lantern Pharma has market cap of $28M and EV of $18M.
Equity research analysts estimate Lantern Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lantern Pharma has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV (current) | $18M | XXX | $18M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| P/E | (1.6x) | XXX | (1.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lantern Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lantern Pharma Margins & Growth Rates
Lantern Pharma's revenue in the last fiscal year grew by —.
Lantern Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Lantern Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lantern Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Klaria Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lantern Pharma M&A Activity
Lantern Pharma acquired XXX companies to date.
Last acquisition by Lantern Pharma was on XXXXXXXX, XXXXX. Lantern Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lantern Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLantern Pharma Investment Activity
Lantern Pharma invested in XXX companies to date.
Lantern Pharma made its latest investment on XXXXXXXX, XXXXX. Lantern Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lantern Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lantern Pharma
| When was Lantern Pharma founded? | Lantern Pharma was founded in 2013. |
| Where is Lantern Pharma headquartered? | Lantern Pharma is headquartered in United States. |
| How many employees does Lantern Pharma have? | As of today, Lantern Pharma has over 24 employees. |
| Who is the CEO of Lantern Pharma? | Lantern Pharma's CEO is Panna L. Sharma. |
| Is Lantern Pharma publicly listed? | Yes, Lantern Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Lantern Pharma? | Lantern Pharma trades under LTRN ticker. |
| When did Lantern Pharma go public? | Lantern Pharma went public in 2020. |
| Who are competitors of Lantern Pharma? | Lantern Pharma main competitors are Jasper Therapeutics, Elicera Therapeutics, Tempest Therapeutics, Marker Therapeutics. |
| What is the current market cap of Lantern Pharma? | Lantern Pharma's current market cap is $28M. |
| Is Lantern Pharma profitable? | No, Lantern Pharma is not profitable. |
| What is the current net income of Lantern Pharma? | Lantern Pharma's last 12 months net income is ($18M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.